Pharmaceutical composition comprising, in combination, saredutant and escitalopram
AssigneeSanofi-Aventis
InventorsGuy Griebel, Caroline Cohen, Caroline Louis, Lisa Ann Arvanitis
Life of this patent
Estimating the term…
Abstract
A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen from (S)-(−)-N-[4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from (S)-(+)-1-[4-(3-(dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile and pharmaceutically acceptable salts thereof.
Claims36
A combination comprising at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from escitalopram and pharmaceutically acceptable salts thereof.
A pharmaceutical composition comprising at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from escitalopram and pharmaceutically acceptable salts thereof in combination with at least one pharmaceutically acceptable excipient.
A method of treatment of a mood disorder in a patient comprising administering to the patient a therapeutically effective amount of a combination of at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from escitalopram and pharmaceutically acceptable salts thereof optionally in combination with one or more pharmaceutically acceptable excipients.
A method of treatment of an anxiety disorder in a patient comprising administering to the patient a therapeutically effective amount of a combination of at least one active ingredient chosen from saredutant and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from escitalopram and pharmaceutically acceptable salts thereof optionally in combination with one or more pharmaceutically acceptable excipients.
Dependencies are inferred from the claim text.